https://www.selleckchem.com/products/dw71177.html
Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) versus placebo plus BSC in patients with HCC who previously received sorafenib. This study presents the results of a prespecified exploratory analysis of patient-reported outcomes. Patients completed the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORT
Like
Comment
Share
